ESAB
ESAB
$64.51
-1.29%
ESAB Corporation, spun off from Colfax in 2022 and listed on the NYSE, manufactures welding, cutting, and joining equipment and consumables used across industrial fabrication, construction, and energy end-markets, generating roughly $2.8 billion in revenue in 2025. Alongside Lincoln Electric and ITW's Miller brand, ESAB is one of the top three global players in welding, with a portfolio spanning equipment (the dominant revenue line at approximately $1.41 billion) and a smaller consumables business, plus a footprint of 10,300 employees and a market capitalization near $6.8 billion. The investor narrative has turned sharply negative: the stock has lost roughly 46% over the past year and 42% year-to-date, with the most recent quarterly print showing gross margin compression to 30.5% from 38.5% a year earlier and a steep sequential drop in net income, fueling debate over whether this is a cyclical industrial downturn, integration/restructuring noise, or genuine share loss to competitors. Bulls point to a forward PE near 10x, a strong_buy consensus, and a 17.3% operating margin as evidence the selloff is overdone, while bears focus on decelerating momentum, elevated leverage relative to cash generation, and a 5.35 short ratio suggesting persistent skepticism.…
ESAB
ESAB
$64.51
ESAB 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on ESAB's 12-month outlook, with a consensus price target around $123.64 and implied upside of +91.7% versus the current price.
Average Target
$123.64
0 analysts
Implied Upside
+91.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$95 - $145
Analyst target range
Coverage is robust with 11 analysts, and the consensus is emphatically bullish: the recommendation is "strong_buy" with a mean rating of 1.27 (where 1.0 is a strong buy), and the average target price of $123.64 implies roughly +89% upside from the current $65.35 — an unusually large gap that signals either a significant mispricing or stale targets that have not yet been revised downward. The consensus EPS estimate of $9.86 and revenue estimate of $3.78 billion imply analysts expect a sharp earnings recovery, which stands in stark contrast to the latest quarterly EPS of $0.55 and the margin compression trend, suggesting the targets may lag reality.
The target range of $95.00 to $145.00 is wide (a $50 spread, or roughly 53% of the low end), indicating high uncertainty about the recovery path. The high target of $145 assumes multiple expansion back toward prior highs and successful margin normalization, while even the low target of $95 implies +45% upside — meaning every analyst on the Street sees the stock as undervalued, a uniformity that itself warrants caution given the -46% one-year decline. Institutional ratings show a pattern of reiterations rather than fresh upgrades: Stifel, JP Morgan, Roth Capital, Oppenheimer, and UBS have all maintained Buy/Overweight/Outperform ratings through February 2026 with no downgrades, but the absence of recent upgrades or target cuts suggests analysts are holding steady rather than actively re-underwriting the name — a dynamic that could resolve violently in either direction when estimates are next revised.
Bulls vs Bears: ESAB Investment Factors
The bear case currently holds stronger near-term evidence: an ~800bps gross margin collapse, EPS falling to $0.55 from $0.89, and a stock pinned 3.5% above its 52-week low with -61.8 points of relative underperformance versus SPY. The bull case rests almost entirely on the forward earnings bridge — a 10.14x forward PE and a $123.64 consensus target — which requires margins to normalize sharply from Q4 levels. The single most important tension is whether the Q4 gross margin compression is cyclical/transitory (restructuring, mix, one-time costs) or structural share loss to Lincoln Electric and Miller; if margins recover toward the 35.5% TTM level, the forward PE makes the stock deeply undervalued, but if 30% gross margins persist, the $9.86 consensus EPS is unreachable and targets must fall. Until there is evidence of margin stabilization, the risk/reward is asymmetric only for investors willing to underwrite a turnaround.
Bullish
- Forward PE of 10.1x implies deep discount: At $65.35, ESAB trades at 10.14x the $9.86 consensus EPS versus a trailing PE of 30.03x and a market forward multiple near 20x. If even a portion of the analyst earnings bridge is achieved, the stock is priced for a severe downturn that may already be discounted.
- Analyst consensus uniformly bullish: All 11 covering analysts rate the stock strong_buy (mean 1.27), with an average target of $123.64 implying +89% upside and even the lowest target of $95.00 implying +45%. No downgrades have been issued through February 2026, suggesting the Street views the selloff as overdone.
- Solid core profitability and cash generation: Despite the Q4 margin shock, TTM operating margin is 17.30% and TTM free cash flow is $213.28 million, a 3.1% FCF yield on the $6.81 billion market cap. The business remains profitable with a 7.98% net margin and ROE of 10.47%, not a distressed profile.
- Revenue still growing modestly: Q4 2025 revenue of $720.99 million rose 7.49% year-over-year from $670.76 million, and the trailing four-quarter run-rate of roughly $2.84 billion shows the top line has not collapsed. Volume resilience supports the view that this is margin noise rather than demand destruction.
Bearish
- Gross margin collapse of ~800bps: Q4 2025 gross margin fell to 30.47% from 38.51% a year earlier and 37.63% in Q1 2025, a roughly 800-basis-point compression. This is the single most damaging data point and directly undermines the forward earnings bridge analysts rely on.
- Earnings quality deterioration: Q4 EPS fell to $0.55 from $0.89 a year earlier, and the reported $166.24 million operating income was inflated by a $102.18 million non-operating gain; excluding it, core operating margin was closer to 8-9%. The trailing EPS metric of 0.033 suggests the latest period was barely profitable.
- Falling-knife technicals at 52-week lows: The stock is down 46.28% over one year and 41.95% YTD, trading just 3.5% above its $62.74 52-week low and 52.4% below its $137.42 high, with a max drawdown of -52.11%. It has underperformed SPY by 61.81 percentage points over one year with no durable base formed.
- Stale analyst targets risk sharp revisions: The $123.64 average target implies +89% upside, an unusually wide gap that likely reflects targets not yet re-underwritten against the Q4 margin miss. The $50 spread between the $95 low and $145 high signals high uncertainty and raises the risk of a violent downward revision cycle.
ESAB Technical Analysis
ESAB is in a pronounced, sustained downtrend, with the 1-year price change of -46.28% and a YTD decline of -41.95% placing the current price of $65.35 at just 3.5% above its 52-week low of $62.74 and roughly 52.4% below its 52-week high of $137.42 — effectively trading at the very bottom of its 52-week range (about 3.5% of the range from the low). This positioning signals a falling-knife dynamic rather than a value opportunity: the stock has given back more than half its value from peak (max drawdown of -52.11%), and there is no evidence yet of a durable base. Relative strength confirms the damage, with the stock underperforming SPY by 61.81 percentage points over one year and 53.88 points YTD.
Short-term momentum remains weak but is decelerating in its rate of decline: the 1-month change of -1.70% and 3-month change of -27.21% show the sharpest damage occurred in the July-September window (from roughly $98 in early July to the mid-$60s by late September), while the last month has been roughly flat-to-slightly-down, hinting at possible stabilization near $64-66. That said, the 1-month relative strength of -2.92 points versus SPY's +1.22% shows ESAB is still lagging a rising market, a bearish divergence. The stock printed a recent low of $64.56 on October 14 and closed at $65.35 on October 16, with the previous session at $65.63 — a tight three-day range that suggests sellers are losing urgency but buyers have not yet stepped in; volume of roughly 1.32 million shares is unremarkable, offering no capitulation signal.
Key technical levels are well defined: support sits at the 52-week low of $62.74, and a breakdown below that level would likely trigger momentum-driven selling and open the door to new lows, while resistance is anchored at the 52-week high of $137.42, with intermediate resistance likely in the $75-80 zone where the stock repeatedly failed in August and September. A reclaim of $75 would be the first meaningful sign of a trend change; a break of $62.74 would confirm the downtrend. With a beta of 1.143, ESAB is about 14% more volatile than the market, meaning position sizing should account for amplified drawdowns — a 10% market decline would historically imply roughly an 11-12% move in ESAB, though the stock's idiosyncratic -46% one-year decline shows company-specific risk has dominated market beta.
Beta
1.14
1.14x market volatility
Max Drawdown
-52.1%
Largest decline past year
52-Week Range
$63-$137
Price range past year
Annual Return
-47.1%
Cumulative gain past year
| Period | ESAB Return | S&P 500 |
|---|---|---|
| 1m | -0.7% | +0.6% |
| 3m | -25.0% | +2.4% |
| 6m | -37.9% | +7.8% |
| 1y | -47.1% | +15.4% |
| ytd | -42.7% | +12.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ESAB Fundamental Analysis
Revenue is growing but at a modest pace and with deteriorating quality: Q4 2025 revenue of $720.99 million rose 7.49% year-over-year versus $670.76 million in Q4 2024, and the trailing four-quarter run-rate of roughly $2.84 billion (Q1 $678.1M, Q2 $715.6M, Q3 $727.8M, Q4 $721.0M) is essentially flat sequentially, indicating low single-digit organic growth at best. The segment mix is heavily skewed toward equipment ($1.41 billion) versus consumables ($42.7 million as reported), which matters because equipment is more cyclical and consumables carry higher recurring margins — a mix that leaves ESAB more exposed to capex cycles in industrial end-markets. Analyst estimates for revenue of approximately $3.78 billion imply expectations of meaningful acceleration, which the current quarterly trajectory does not yet support, making the growth outlook a key risk to the investment case.
Profitability has deteriorated sharply at the margin level: Q4 2025 gross margin fell to 30.47% from 38.51% in Q4 2024 and 37.63% in Q1 2025, a roughly 800-basis-point year-over-year compression that drove net income down to $37.67 million (5.23% net margin) from $53.74 million a year earlier, despite higher revenue. Operating income of $166.24 million in Q4 (23.06% operating margin) was inflated by a $102.18 million non-operating gain in other income, masking weaker core profitability — the operating margin excluding that item would be closer to 8-9%. The company remains solidly profitable on a trailing basis (net margin 7.98%, operating margin 17.30%), but the trend is negative: EPS fell from $0.89 in Q4 2024 to $0.55 in Q4 2025, and the 0.0334 trailing EPS figure in the key metrics suggests the most recent period was barely profitable, a red flag for the forward earnings story.
Balance sheet health is adequate but not fortress-like: debt-to-equity of 0.66 and a current ratio of 1.90 provide reasonable liquidity, while TTM free cash flow of $213.28 million against a $6.81 billion market cap yields roughly 3.1% — respectable but not cheap for a declining stock. The concern is cash conversion quality: Q4 2025 operating cash flow of $97.05 million against net income of $226.77 million (TTM basis) reflects heavy working capital drag (-$38.9 million change in working capital) and a $19.6 million capex outlay, and the cash-flow-to-debt ratio of 0.068 is low, indicating limited debt-service cushion from operations. ROE of 10.47% and ROA of 5.0% are middling for an industrial, and with interest coverage of 9.27x, the company can service its debt but has limited room for a prolonged earnings downturn without leaning on external financing.
Quarterly Revenue
$720986000.0B
2025-12
Revenue YoY Growth
+7.5%
YoY Comparison
Gross Margin
30.5%
Latest Quarter
Free Cash Flow
$213280000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ESAB Overvalued?
Because ESAB is profitable (net income positive at $37.67 million in the latest quarter and $226.77 million TTM), the PE ratio is the appropriate primary metric: the trailing PE of 30.03x looks expensive, but the forward PE of 10.14x tells a very different story, implying the market expects earnings to roughly triple. That enormous gap between trailing and forward multiples is the crux of the valuation debate — it reflects either a trough-earnings year that will normalize (bull case) or analyst estimates that are too optimistic given the margin compression trend (bear case). The PEG ratio of -2.05 is not meaningful given negative growth assumptions in the calculation, and the PS ratio of 2.40x and EV/Sales of 2.21x provide a cleaner read on the revenue-based valuation.
Against the broader industrials/manufacturing sector, ESAB's 2.40x PS and 2.21x EV/Sales are not obviously cheap — many metal fabrication peers trade in the 1.5-2.5x sales range — while the 16.38x EV/EBITDA sits at a modest premium to typical industrial multiples of 10-12x, suggesting the market is still paying for quality despite the selloff. The 10.14x forward PE, however, is a meaningful discount to the market's ~20x forward multiple and to industrial peers, which is the strongest argument for the bull case: if the $9.86 consensus EPS estimate is achieved, the stock is cheap. The risk is that the 30.47% gross margin in Q4 versus the 35.54% TTM figure implies further compression, which would invalidate the forward earnings bridge.
Historically, ESAB's PE has ranged from roughly 9.6x (Q3 2022) to 45.2x (Q4 2025), with the PS ratio ranging from about 3.2x (Q3 2022) to 10.8x (Q4 2024) — the current 2.40x PS is near the low end of that historical band, while the 30.03x trailing PE is elevated only because earnings have collapsed. The stock's price-to-book of 3.14x compares with a historical range of roughly 1.2x to 4.1x, placing it in the middle of its own band. Net-net, the valuation is bifurcated: cheap on forward earnings and sales relative to history, expensive on trailing earnings and EBITDA, meaning the stock's direction will hinge almost entirely on whether margins stabilize in the coming quarters.
PE
30.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 10x~45x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the margin collapse and earnings quality. Q4 2025 gross margin of 30.47% versus 38.51% a year earlier represents roughly 800bps of compression, and reported operating income of $166.24 million was flattered by a $102.18 million non-operating gain — excluding it, core operating margin was closer to 8-9%. Net income fell to $37.67 million (5.23% margin) from $53.74 million despite 7.49% revenue growth, and with debt-to-equity of 0.66, a cash-flow-to-debt ratio of only 0.068, and interest coverage of 9.27x, the company has limited cushion if earnings keep deteriorating. Revenue is also concentrated in cyclical equipment ($1.41 billion) versus higher-margin recurring consumables, leaving ESAB exposed to industrial capex cycles.
Market and competitive risks are elevated by the stock's positioning and sentiment. ESAB trades at 16.38x EV/EBITDA, a premium to typical industrial multiples of 10-12x, so there is room for further multiple compression if margins stay depressed; the 30.03x trailing PE is expensive only because earnings have collapsed. With a beta of 1.143, the stock is ~14% more volatile than the market, but its -46% one-year decline shows idiosyncratic risk has dominated — it underperformed SPY by 61.81 points. A 5.35 short ratio signals persistent bearish positioning, and the risk of analyst target cuts (average $123.64 versus a $65.35 price) could trigger another leg down if estimates are re-underwritten.
Worst-case scenario: the Q4 gross margin weakness proves structural (share loss to Lincoln Electric/Miller or persistent input cost pressure), the $9.86 consensus EPS is cut sharply, and analysts slash targets toward the $95 low or below. In that chain, the stock breaks its $62.74 52-week low, opening momentum-driven selling toward the mid-$50s — a further -15% to -20% from $65.35. A retest of the 52-week low alone implies roughly -4%, but a full de-rating to the historical low-end PS multiple of ~3.2x on lower revenue, or a move toward the -52.11% max drawdown level, could put the stock in the $50s, representing -20% to -25% downside from current levels.